ALK and non-small cell lung carcinoma: The results of a phase II clinical study of Benjamin et al. showed that the intracranial ORR of ALK-positive patients with NSCLC treated with lorlatinib was 66.7% in treatment-naive patients and 63% in patients with at least one prior ALK-TKI treatment [97].